{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001577","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.922026+00:00","generated_at":"2026-06-18T05:14:26.355112+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Harvard Bioscience approves 2023 cash incentive plan for CEO and Interim CFO","bullets":["Compensation Committee approved 2023 annual cash incentive plan on March 6, 2023.","CEO and Interim CFO receive target award as a percentage of 2023 base salary.","Payout can range from 0% to 150% of target based on corporate financial objectives.","No specific targets, dollar amounts, or performance thresholds disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001577","json":"https://secwatch.observer/filing/0001171843-23-001577.json","markdown":"https://secwatch.observer/filing/0001171843-23-001577.md","text":"https://secwatch.observer/filing/0001171843-23-001577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323001577/0001171843-23-001577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323001577/f8k_031023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:14:26.355112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}